ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2021
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis.Scientific reports · 2025Pooled it
- A pragmatic workflow for advanced NSCLC diagnosis in routine practice: Integrating histopathology, PD-L1 scoring, and EGFR testing.Lung India : official organ of Indian Chest Society · 2026Article
- Comprehensive molecular characterization of cfDNA as predictive and monitoring biomarkers in advanced gastric cancer receiving immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Immune checkpoint inhibitors in medulloblastoma: current updates in preclinical and clinical developments.Frontiers in oncology · 2026Review
- PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.Thoracic cancer · 2025Review
- Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Nature medicine · 2025Article
- InterobServer AgreeMent in Pd-l1 evaLuatIoN on cytoloGical samples-SAMPLING project: A multi-institutional, international study.Cancer cytopathology · 2025Article
- Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications.Frontiers in oncology · 2025Review
- Review
- Improving practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions.Journal of clinical pathology · 2024Article
- Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- Comments on the Article by Miura et al.: "Comparable Clinical Benefit Between Different Subsets Selected by PD-L1 22C3 and SP142 Tests".JTO clinical and research reports · 2023Article
- Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.The oncologist · 2022Article
- Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer.Disease markers · 2022Article
- Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide.CA: a cancer journal for cliniciansArticle
Corrections and comments
- Erratum issuedErratum.2021
Authors and funding
39 authors at 20 institutions in 15 countries.
Funding
Abstract
introductionProgrammed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is required to determine the eligibility for pembrolizumab monotherapy in advanced NSCLC worldwide and for several other indications depending on the country. Four assays have been approved/ Communauté Européene-In vitro Diagnostic (CV-IVD)-marked, but PD-L1 IHC seems diversely implemented across regions and laboratories with the application of laboratory-developed tests (LDTs).
methodTo assess the practice of PD-L1 IHC and identify issues and disparities, the International Association for the Study of Lung Cancer Pathology Committee conducted a global survey for pathologists from January to May 2019, comprising multiple questions on preanalytical, analytical, and postanalytical conditions.
resultA total of 344 pathologists from 64 countries participated with 41% from Europe, 24% from North America, and 18% from Asia. Besides biopsies and resections, cellblocks were used by 75% of the participants and smears by 11%. The clone 22C3 was most often used (69%) followed by SP263 (51%). They were applied as an LDT by 40% and 30% of the users, respectively, and 76% of the participants developed at least one LDT. Half of the participants reported a turnaround time of less than or equal to 2 days, whereas 13% reported that of greater than or equal to 5 days. In addition, quality assurance (QA), formal training for scoring, and standardized reporting were not implemented by 18%, 16%, and 14% of the participants, respectively.
conclusionsHeterogeneity in PD-L1 testing is marked across regions and laboratories in terms of antibody clones, IHC assays, samples, turnaround times, and QA measures. The lack of QA, formal training, and standardized reporting stated by a considerable minority identifies a need for additional QA measures and training opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.